Interactions of cations and anions with the binding of uptake blockers to the dopamine transporter

被引:5
作者
Bonnet, JJ [1 ]
机构
[1] IFRMP, UMR CNRS 6036, Lab Neuropsychopharmacol Expt, F-76000 Rouen, France
关键词
DAT (dopamine transporter); cation; anion; binding; uptake blocker;
D O I
10.1016/j.ejphar.2003.08.069
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Uptake blockers and substrates are likely to recognise a common binding domain on the dopamine neuronal transporter (DAT). Among cations that form ionic gradients at the level of the cellular plasma membrane, Na+ is the only one that can stimulate their binding. The binding stimulation appears over Na+ concentrations ranging from 0 to 10-60 mM; at higher Na+ concentrations, binding reaches a plateau or decreases, according to the uptake blocker that is studied. The majority of the other cations, including K+, Ca2+, Mg2+ and Tris(+), inhibit the binding of uptake blockers. Several metals impair binding to the DAT and/or the dopamine transport, but, under specific conditions, some of them, and chiefly Zn2+, stimulate binding. The complex relationships between cations, uptake blockers and the DAT suggest that cations recognise at least three different sites: the first one, site 1, is for cation-induced binding inhibition; the second one, site 2, is for Na+-induced binding stimulation; and the third one, site 3, is for Zn2+-induced binding stimulation. Modelling of the interactions between Na+, K+ and radioligands allows a better understanding of the effects of cations at sites 1 and 2, and of uptake blockers at site 1. Some anions also facilitate the binding of uptake blockers to the DAT, as far as they are associated with Na+. The dependence of the binding of dopamine on ions could be involved in its preferential inward transport and used by uptake blockers for their own binding to the DAT. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:199 / 212
页数:14
相关论文
共 75 条
[51]   Delineation of an endogenous zinc-binding site in the human dopamine transporter [J].
Norregaard, L ;
Frederiksen, D ;
Nielsen, EO ;
Gether, U .
EMBO JOURNAL, 1998, 17 (15) :4266-4273
[52]  
REFAHILYAMANI F, 1995, N-S ARCH PHARMACOL, V351, P136
[53]  
Reith MEA, 1998, METHOD ENZYMOL, V296, P248
[54]   CATIONIC AND ANIONIC REQUIREMENTS FOR THE BINDING OF 2-BETA-CARBOMETHOXY-3-BETA-(4-FLUOROPHENYL)[3H]TROPANE TO THE DOPAMINE UPTAKE CARRIER [J].
REITH, MEA ;
COFFEY, LL .
JOURNAL OF NEUROCHEMISTRY, 1993, 61 (01) :167-177
[55]   EVIDENCE FOR MUTUALLY EXCLUSIVE BINDING OF COCAINE, BTCP, GBR-12935, AND DOPAMINE TO THE DOPAMINE TRANSPORTER [J].
REITH, MEA ;
DECOSTA, B ;
RICE, KC ;
JACOBSON, AE .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1992, 227 (04) :417-425
[56]   Binding domains for blockers and substrates on the cloned human dopamine transporter studied by protection against N-ethylmaleimide-induced reduction of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)[H-3]tropane ([H-3]WIN 35,428) binding [J].
Reith, MEA ;
Xu, C ;
Coffey, LL .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (09) :1435-1446
[57]   The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter [J].
Reith, MEA ;
Berfield, JL ;
Wang, LC ;
Ferrer, JV ;
Javitch, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :29012-29018
[58]  
REITH MEA, 1992, N-S ARCH PHARMACOL, V345, P309
[59]  
RICHFIELD EK, 1993, MOL PHARMACOL, V43, P100
[60]   COCAINE AND GBR-12783 RECOGNIZE NONIDENTICAL, OVERLAPPING BINDING DOMAINS ON THE DOPAMINE NEURONAL CARRIER [J].
SAADOUNI, S ;
REFAHILYAMANI, F ;
COSTENTIN, J ;
BONNET, JJ .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 268 (02) :187-197